[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Hasegawa Y, Tomita K, Hashimoto K, Shigeoka Y, Watanabe M, Yamasaki A, Shimizu E: Des-gamma-carboxy prothrombin (PIVKA-II)-producing mediastinal embryonal carcinoma with features of hepatoid differentiation. Anticancer Res; 2005 Nov-Dec;25(6C):4569-71
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Des-gamma-carboxy prothrombin (PIVKA-II)-producing mediastinal embryonal carcinoma with features of hepatoid differentiation.
  • The case of a 48-year-old man with primary nonseminomatous embryonal carcinoma at the posterior mediastinum is described.
  • The patient displayed extremely high plasma levels of Des-gamma-carboxy prothrombin (PIVKA-II) (4040 mAU/ml).
  • Ultrasonography and dynamic computed tomography ruled out hepatocellular carcinoma (HCC) or liver metastasis.
  • After preoperative systemic chemotherapy, total tumor resection was performed.
  • An immnohistochemical study using anti-PIVKA-II monoclonal antibody revealed the cytoplasmic expression of PIVK4-II in the carcinoma cells.
  • This case seems to be the first case reported in which PIVKA-II was produced by nonseminomatous mediastinal embryonal carcinoma without HCC or liver metastasis.
  • [MeSH-major] Biomarkers / blood. Carcinoma, Embryonal / blood. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Mediastinal Neoplasms / blood. Protein Precursors / blood

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • Genetic Alliance. consumer health - Prothrombin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334143.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Protein Precursors; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


2. Tanase K, Tawada M, Moriyama N, Muranaka K: [Intra-arterial infusion chemotherapy for liver metastases of testicular tumors: report of two cases]. Hinyokika Kiyo; 2000 Nov;46(11):823-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-arterial infusion chemotherapy for liver metastases of testicular tumors: report of two cases].
  • Two cases of testicular tumors with lymph node involvement and multiple lung and liver metastases were treated successfully with intra-arterial infusion chemotherapy.
  • He had a large retroperitoneal mass and multiple lung and liver metastases on computed tomographic (CT) scan and chest X-ray.
  • Histopathological diagnosis revealed embryonal cell carcinoma and choriocarcinoma.
  • Cisplatin, vinblastine, VP-16 and pepleomycin combination chemotherapy (PVeBV) was started and repeated for 2 courses.
  • The retroperitoneal mass and lung tumors decreased in size, but liver tumors enlarged.
  • Systemic and intrahepatic arterial infusion combined with chemotherapy was administered, and intra-arterial chemotherapy (cisplatin, VP-16) was added.
  • The patient also received systemic chemotherapy (carboplatin, VP-16, ifosfamide).
  • After chemotherapy, retroperitoneal lymph node dissection was performed.
  • On CT scan, no retroperitoneal, liver, or lung tumor was detected.
  • CT scan revealed a large retroperitoneal mass as well as lung and multiple liver metastases.
  • Cisplatin, vinblastine, VP-16 and pepleomycin combination chemotherapy (PVeBV) was administered, but the liver tumors ware enlarged on CT scan.
  • Intrahepatic arterial infusion chemotherapy (cisplatin, VP-16) was started and repeated for 4 courses.
  • On CT scan, the lung metastasis seemed to have disappeared, and the retroperitoneal mass and liver metastases were decreased in size.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Embryonal / secondary. Choriocarcinoma / secondary. Liver Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Infusions, Intra-Arterial. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasms, Multiple Primary. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193306.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; PVeBV protocol
  • [Number-of-references] 13
  •  go-up   go-down


3. Tietze MK, Wuestefeld T, Paul Y, Zender L, Trautwein C, Manns MP, Kubicka S: IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther; 2000 Oct;7(10):1315-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas.
  • The transcription factor nuclear factor kappaB (NFkappaB) is an essential antagonist of apoptosis during liver regeneration and embryonal development of hepatocytes.
  • Several reports have indicated that NFkappaB may also inhibit the programmed cell death induced by cytokines, ionizing radiation, or cytotoxic drugs in some cancer cell lines.
  • Because hepatocellular carcinomas (HCCs) are one of the most resistant tumors to systemic chemotherapy, we investigated the activation of NFkappaB and the consequence of its inhibition by an IkappaBalpha-super repressor during tumor necrosis factor alpha (TNFalpha)- and chemotherapy-induced apoptosis in HCC cell lines.
  • Inhibition of NFkappaB enhanced the apoptosis induced by TNFalpha, whereas IkappaBalpha had an anti-apoptotic effect on chemotherapy-induced programmed cell death.
  • A strong inhibition of chemotherapy- and TNFalpha-induced apoptosis by dominant-negative Fas-associated death domain indicated an essential contribution of death receptor-mediated apoptosis.
  • To elucidate the different role of NFkappaB in chemotherapy-induced apoptosis, we investigated the expression of Fas (CD95) and Fas ligand (CD95 ligand), which have been described as important mediators of chemotherapy-induced cell death and as target genes of NFkappaB.
  • However, our investigations demonstrated that in hepatoma cells, the chemotherapy-induced up-regulation of Fas (CD95) and Fas ligand (CD95 ligand) is not transcriptionally mediated through NFkappaB.
  • In summary, our investigations indicate that the activation of NFkappaB in response to cytotoxic drugs, in contrast to TNFalpha, exerts a pro-apoptotic stimulus rather than an anti-apoptotic function, which has implications for therapy of HCCs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Carcinoma, Hepatocellular / therapy. DNA-Binding Proteins / genetics. Doxorubicin / pharmacology. Genetic Therapy / methods. I-kappa B Proteins. Liver Neoplasms / therapy. NF-kappa B / antagonists & inhibitors. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Adenoviridae / genetics. Antigens, CD95 / metabolism. Antigens, CD95 / physiology. Blotting, Western. Caspases / metabolism. Drug Resistance. Electrophoresis, Agar Gel. Fas Ligand Protein. Flow Cytometry. Humans. Membrane Glycoproteins / metabolism. Structure-Activity Relationship. Transfection. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059688.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / I-kappa B Proteins; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspases
  •  go-up   go-down


Advertisement
4. Funahashi M, Tuchiya F, Makiyama K, Sugiura S, Miyoshi Y, Kishida T, Ogawa T, Uemura H, Yao M, Kubota Y: [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report]. Hinyokika Kiyo; 2005 Feb;51(2):133-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2002, chemotherapy was performed for a metastatic seminoma revealed as a solitary mass in the mediastinum by radiographic studies, and histologically confirmed to be a metastatic seminoma.
  • The subfraction profile with lens culinaris hemagglutinin (LCA) revealed elevation of only peak 1 which implied that the chronic hepatitis was due to liver dysfunction.
  • Case 2: In 2002, a 30-year-old male underwent left high orchiectomy for a left testicular tumor, and histological examination revealed seminoma, immature and mature teratoma, embryonal carcinoma.
  • After 2 courses of chemotherapy, the serum AFP remained at an abnormally high concentration.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Embryonal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminoma / diagnosis. Teratoma / diagnosis. Testicular Neoplasms / diagnosis. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Follow-Up Studies. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773370.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


5. von Schweinitz D, Faundez A, Teichmann B, Birnbaum T, Koch A, Hecker H, Glüer S, Fuchs J, Pietsch T: Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer; 2000 Jan 15;85(2):151-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapid growth of residual tumor after partial hepatectomy has been observed during the period of liver regeneration in children with malignant embryonal hepatoblastoma.
  • Markedly increased serum levels of HGF-SF up to 15 ng/ml were found in 13/18 patients after liver resection and in 6/16 patients with regressive tumors after chemotherapy, in comparison with 15 patients with non-pre-treated hepatoblastoma and 20 healthy children of the same age group.
  • In contrast, the hepatocellular-carcinoma cell line HepG2 decreased growth under HGF-SF in a dose-dependent manner.
  • [MeSH-major] Hepatoblastoma / pathology. Hepatocyte Growth Factor / physiology. Liver Neoplasms / pathology


6. Akerboom-Straberger BM, Lotgering FK: Embryonal sarcoma of the liver in pregnancy, associated with HELLP syndrome. Am J Obstet Gynecol; 2004 Feb;190(2):556-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal sarcoma of the liver in pregnancy, associated with HELLP syndrome.
  • After cesarean section, a 30-year-old patient with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count in association with preeclampsia) had fever, jaundice, loss of ascites, and a cardiac murmur.
  • Magnetic resonance imaging showed a tumor extending from the left lobe of the liver into the inferior vena cava, right atrium, and ventricle.
  • The biopsy specimen revealed an embryonal sarcoma of the liver.
  • On the second day of chemotherapy, the patient died of intra-abdominal hemorrhage from the tumor.
  • [MeSH-major] Carcinoma, Embryonal / complications. HELLP Syndrome / complications. Liver Neoplasms / complications. Pregnancy Complications, Neoplastic


7. Pectasides D, Skarlos D, Dimopoulos AM, Farmakis D, Pectasides M, Fountzilas G, Aravantinos G: Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res; 2003 Sep-Oct;23(5b):4239-44
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
  • BACKGROUND: We investigated the efficacy and safety of 2 cycles of adjuvant chemotherapy with carboplatin, etoposide and bleomycin (CEB90) in patients with high-risk clinical stage I or stage IM non-seminomatous germ cell tumours (NSGCT).
  • PATIENTS AND METHODS: A total of 52 consecutive patients (22 patients with high-risk histological features [vascular invasion, presence of embryonal carcinoma, absence of yolk sac tumour] and 30 with tumour marker activity post-orchidectomy-stage IM) were entered into this prospective study.
  • Chemotherapy consisted of carboplatin 400 mg/m2 or AUC 5 (day 1), etoposide 165 mg/m2 (days 1-3) and bleomycin 30 mg (days 1, 8, 15).
  • Chemotherapy was repeated every 3 weeks.
  • These cases had a disseminated, marker-positive germ cell tumour (GCT), extensively involving both liver and lungs in the first case and para-aortic lymph nodes and lung in the second one; both patients died of the tumour after a number of salvage chemotherapy (including high-dose therapy) regimens.
  • CONCLUSION: Despite the general consensus that ciplatin-based chemotherapy is superior to carboplatin-containing regimens in testicular cancer, 2 cycles of CEB90 may be an equally effective treatment option as adjuvant therapy for high-risk clinical stage I and IM patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / surgery. Chemotherapy, Adjuvant. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Neoplasm Staging. Orchiectomy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666633.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JEB protocol
  •  go-up   go-down


8. Szumera M, Czauderna P, Popadiuk S, Gołebiewski J, Sznurkowska K, Renke J, Korzon M: [Assessment of treatment results in children with malignant liver tumours in own experience]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):539-49
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of treatment results in children with malignant liver tumours in own experience].
  • AIM: The assessment of malignant liver tumours in children treated in our centre between years 1985-2004 has been made in order to analyze the prognostic factors and improvement in survival rate.
  • MATERIAL AND METHODS: 17 patients with malignant liver tumours were followed-up.
  • There were 10 (58,8%) patients with hepatoblastomas, 5 (29,4%) hepatocarcinomas, 1 (5,9%) undifferentiated embryonal sarcoma and 1 (5,9%) rhabdomyosarcoma.
  • Primary metastatic disease was recognized in 3 cases as: hepatic vascular involvement, lungs, femoral bone and lymph nodes of liver hilus metastases.
  • All patients underwent preoperative chemotherapy.
  • Secondary metastases appeared in lungs, lymph nodes of liver hilus and central nervous system in 4 cases.
  • RESULTS: Twelve patients are alive with median follow-up 34,0 mths, five died with median survival time 16,0 mths.
  • Total excision of liver tumour had no statistical significance in lifetime prolongation (p =0,12).
  • CONCLUSIONS: Complete surgical excision had no statistical significance in increasing survival time in liver tumour patients.
  • Metastatic disease had statistical significance in shortening overall survival of patients with liver tumours.
  • Unsatisfactory results in hepatocarcinoma treatment in children dramatically demonstrate the need for new treatment approaches.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Hepatocellular. Child. Child, Preschool. Female. Follow-Up Studies. Hepatoblastoma / pathology. Hepatoblastoma / secondary. Hepatoblastoma / therapy. Humans. Infant. Male. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Oncology Service, Hospital / statistics & numerical data. Poland. Retrospective Studies. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719167.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Kalteis T, Heers G, Elsner R: Adenocarcinoma of the rectum in childhood following chemotherapy and radiotherapy for a rhabdomyosarcoma--a case report. Eur J Pediatr Surg; 2005 Jun;15(3):210-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the rectum in childhood following chemotherapy and radiotherapy for a rhabdomyosarcoma--a case report.
  • We report a case of rectal adenocarcinoma in a 9-year-old boy, which took the form of a second malignant neoplasm following treatment for an early childhood malignancy.
  • The abdominal complaints were for a long time interpreted as an infectious disease.
  • At the time of diagnosis of the rectal carcinoma, the tumor had already progressed to the stage of metastatic disease.
  • Therapy consisted of deep anterior rectal resection and regional arterial chemotherapy for liver metastases.
  • The child died 18 months after the diagnosis of rectal carcinoma.
  • This phenomenon emphasizes the need for continued clinical surveillance of patients who have been treated with chemotherapy or irradiation for childhood tumors.
  • The increased risk of second malignant neoplasms and an early onset of adult-type tumors has to be considered.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasms, Second Primary. Rectal Neoplasms / surgery. Rhabdomyosarcoma, Embryonal / drug therapy. Rhabdomyosarcoma, Embryonal / radiotherapy
  • [MeSH-minor] Child. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Thigh

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999318.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Minowada S, Okano Y, Miyazaki J, Homma Y, Kitamura T: Multidisciplinary treatment of advanced testicular tumor with bulky liver metastasis. Urol Int; 2001;67(2):178-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary treatment of advanced testicular tumor with bulky liver metastasis.
  • He had multiple bulky metastases in the liver and retroperitoneum with an extraordinarily elevated serum alpha-fetoprotein (23,500 ng/ml).
  • He received multidisciplinary treatment consisting of systemic chemotherapy, cytoreductive left hepatic lobectomy, percutaneous ablation therapy, transarterial chemoembolization, and external beam irradiation for median segments of the liver.
  • The efficient combination treatment normalized the tumor markers within 6 months and has maintained complete serological remission for 4.7 years.
  • [MeSH-major] Carcinoma, Embryonal / secondary. Endodermal Sinus Tumor / secondary. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoplasms, Multiple Primary / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel.
  • (PMID = 11490219.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Sasaki K, Kasahara M, Fukuda A, Shigeta T, Tanaka H, Nakagawa S, Mitsui K, Harada R, Nakagawa A: Living donor liver transplantation for hepatoblastoma with Beckwith-Wiedemann syndrome. Pediatr Transplant; 2010 Nov;14(7):E89-92
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for hepatoblastoma with Beckwith-Wiedemann syndrome.
  • BWS is one of the most well-known somatic overgrowth syndromes, which is characterized by macroglossia, organomegaly, abdominal wall defects, and predisposition to embryonal tumors, such as Wilms' tumor, hepatoblastoma, and adrenocortical carcinoma.
  • We report a case of BWS in a girl with unresectable hepatoblastoma, who received a planned LVDT following neo-adjuvant chemotherapy.
  • This is the first case report of liver transplantation for patients with BWS.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / therapy. Hepatoblastoma / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Female. Humans. Immunosuppressive Agents / therapeutic use. Infant. Living Donors. Methylprednisolone / therapeutic use. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use. Recurrence. Tacrolimus / therapeutic use. Time Factors. Tomography, X-Ray Computed / methods. alpha-Fetoproteins / metabolism


12. Almogy G, Lieberman S, Gips M, Pappo O, Edden Y, Jurim O, Simon Slasky B, Uzieli B, Eid A: Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol; 2004 May;30(4):421-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre.
  • METHODS: From 1997 to 2002 eight patients had liver resection for primary sarcoma of the liver at our institution.
  • The clinical characteristics, imaging findings, surgical procedures, adjuvant therapy and outcome were retrospectively reviewed.
  • There were two patients each with angiosarcoma (AS), leiomyosarcoma (LMS), and undifferentiated embryonal sarcoma (UES), one patient with epithelioid hemangioendothelioma (EHE) and one patient with malignant peripheral nerve sheath sarcoma (PNSS).
  • Preoperative diagnosis of a primary liver sarcoma was made in 7/8 cases, either by fine needle aspiration (n = 5) or angiography (n = 2).
  • Two patients developed complications and there was one death.
  • Systemic chemotherapy led to tumour regression in both patients with UES which enabled a second hepatic resection.
  • CONCLUSIONS: The majority of patients with primary liver sarcoma present with right upper quadrant pain, fever and a liver mass.
  • Differentiating the rare primary liver sarcoma from the much more common hepatocellular carcinoma (HCC) may aid in planning therapy.
  • Liver resection combined with adjuvant chemotherapy are the mainstays of treatment for UES in the adult.
  • [MeSH-major] Liver Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Hepatectomy / methods. Humans. Length of Stay. Liver Function Tests. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15063896.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Rivoire M, Elias D, De Cian F, Kaemmerlen P, Théodore C, Droz JP: Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer; 2001 Aug 1;92(3):578-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery.
  • BACKGROUND: The presence of liver metastases represents an independent poor risk prognostic factor for survival in patients with germ cell tumors.
  • METHODS: The clinical files of 37 patients who had undergone liver resection for the treatment of disseminated germ cell tumors were reviewed to define the indications for resection of residual liver metastases after chemotherapy in patients with germ cell tumors.
  • Three prognostic factors were found to be significant in the univariate analysis for unfavorable outcome: the presence of pure embryonal carcinoma in the primary tumor, liver metastases measuring > 30 mm in greatest dimension at the time of surgery, and the presence of viable, active residual disease.
  • CONCLUSIONS: Because it is impossible to determine the histologic pattern of residual liver masses after chemotherapy with current imaging tools and percutaneous biopsy, patient selection for liver surgery may be undertaken according to the size of residual liver masses.
  • Male patients with masses that measure > or = 30 mm in greatest dimension represent a high-risk group of patients who are not likely to benefit from liver surgery.
  • Only male patients with masses that measure 10-29 mm in greatest dimension and all female patients with masses that measure > 10 mm in greatest dimension should be considered for liver resection.
  • [MeSH-major] Germinoma / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Postoperative Care. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11505402.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Kobayashi N, Koizumi T, Eguchi T, Hyogotani A, Saito G, Hamanaka K, Shiina T, Kurai M, Kondo R, Yoshida K, Amano J: A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities. Anticancer Res; 2010 Dec;30(12):5117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mediastinal somatic-type germ cell tumor with hepatic metastasis successfully treated by multiple modalities.
  • Rhabdomyosarcoma in the mediastinum coexisting with metastatic non-seminomatous germ cell tumor, so-called somatic-type malignancy, is a rare carcinoma and has poor survival.
  • This study reports a case of diffuse and huge hepatic metastasis of non-seminomatous germ cell tumor associated with coexisting embryonal rhabdomyosarcoma in the mediastinum.
  • A 31-year-old man presented with abdominal pain and was found to have multiple abnormal hepatic masses on abdominal computed tomography (CT).
  • Chemotherapy was initiated because the hepatic lesion was diagnosed as choriocarcinoma, based on histological findings and the elevation of chorionic gonadotropin β-subunit and α-fetoprotein.
  • After six cycles of bleomycin, etoposide and cisplatin chemotherapy the metastatic liver tumors showed complete response.
  • The histological findings revealed mature teratoma with embryonal rhabdomyosarcoma.
  • The patient has remained well for over six years after the treatment without any signs of disease recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Mediastinal Neoplasms / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Teratoma / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187499.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Soriano Sarrió P, Chirivella I, Navarro Fos S: [Coexistence of two germinal cell tumors, seminomatous and nonseminomatous, with an uncommon clinical presentation]. Arch Esp Urol; 2008 Jun;61(5):626-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We present a case of pure classic seminoma of the testis with a lymph node metastasis of pure embryonal carcinoma, with confirmatory immuohistochemical study and clinical outcome of the patient.
  • CT scan also revealed multiple metastases in lymph nodes, liver, kidney and left adrenal gland.
  • Tumor markers were negative and the biopsy performed discovered a lymph node metastasis of embryonal carcinoma of probable testicular origin.
  • Currently the patient is being treated with chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709819.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Late recurrences were seen in many different sites in these patients, including the retroperitoneum, abdomen, pelvis, liver, mediastinum, lung, bone (femur, vertebra, and rib), lymph nodes outside the retroperitoneum and mediastinum (supraclavicular, neck, and axillary regions), scrotum and inguinal regions, adrenal gland, chest wall, and buttocks.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Mickisch GH: Prognostic parameters for the management of advanced testis tumours. Curr Opin Urol; 2000 Sep;10(5):465-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the trend for an earlier and more accurate diagnosis amenable to curative treatment as well as the high effectiveness of standard Cisplatinum containing chemotherapy has masked the continuing need for intensifying therapy in patients with adverse risk factors.
  • This intense treatment is often associated with worrysome morbidity and the assessment of prognostic factors, stage by stage, is warranted on which patient at risk can be identified and treated accordingly.
  • Traditional prognostic factors, on which most classification systems are based, include large tumour volume, the presence of liver, bone or brain metastasis, grossly elevated tumour markers and an extragonadal primary site, particularly in the mediastinum.
  • Clearly, the infrastructure and the experience of the treating uro-oncology unit (see 1) is decisive for treatment outcomes, and -at least-'difficult to treat' patients should be referred to properly resourced cancer centres.
  • Finally, biologic factors (see 3) such as beta-human chorionic gonadotrophin or MAGE epitopes in seminoma or the percentage of embryonal carcinoma components orvascular invasion mayor may not inversely influence the prognosis and need further assessment in prospective trials.
  • However, the search for even better (molecular) biologic factors is speeding up because more complex treatment decisions such as in advanced testicular cancers rely on a more precise determination of prognosis, enabling a more tailored selection of individualized therapeutic options.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005453.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


18. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Most patients (52) were stage I, 4 were stage II, 6 stage III, and 1, with liver metastases, stage IV.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Histologically, teratomas were found most frequently (mature: 45, immature: 9), followed by mixed tumors (n = 7), yolk sac tumors (n = 3), dysgerminoma (n = 2), gonadoblastoma (n = 2), and embryonal carcinoma (n = 1).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


19. Czauderna P, Popadiuk S, Korzon M, Stoba C, Szymik-Kantorowicz S, Sawicz-Birkowska K, Lopatka B, Bogusławska-Jaworska J, Kowalczyk J, Sopyło B, Madziara W, Juszkiewicz P, Swiatkiewicz V, Skotnicka-Klonowicz G, Włodarczyk A: Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors--management in a series of 47 Polish patients (1985-1995). Eur J Pediatr Surg; 2001 Apr;11(2):82-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-seven children treated in various Polish centers between 1985 and 1995 for primary malignant liver tumors were retrospectively analyzed.
  • In 44% of HB patients the tumor involved both liver lobes.
  • Chemotherapy was applied in 92% of cases (preoperatively in 67%).
  • Mean observation time was 58 months.
  • Involvement of both lobes of the liver and multifocality of the tumor were other adverse prognostic factors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Poland / epidemiology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371041.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Szumera M, Czauderna P, Popadiuk S, Renke J, Sznurkowska K, Gołebiewski J, Korzon M: [Pulmonary metastases in children with solid tumours--own experiences]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):665-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the moment of the diagnosis lung metastases were present in 19.2% of patients while in the rest (80.8%) occurred during and after treatment.
  • The most often lung metastases were recognised in osteosarcoma (15-57.8%) and carcinoma embryonale (3-11.6%).
  • The after-surgery chemotherapy for tumour recurrence was introduced in each case.
  • RESULTS: In the analysed group 14 (53.8%) children are alive with the overall survival time 8-120 months.
  • The rest 12 (46.2%) are dead with the survival time 6-24 months.
  • Time of occurrence was statistically insignificant (p=0.26).
  • The active search for lung metastases at the moment of diagnosis, treatment and follow-up combined with complete surgery procedures may prolong survival.
  • There is a need to find new methods of lung metastases treatment.
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Carcinoma, Embryonal / secondary. Carcinoma, Embryonal / surgery. Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Child. Endocrine Gland Neoplasms / pathology. Endocrine Gland Neoplasms / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Male. Neuroblastoma / secondary. Neuroblastoma / surgery. Oncology Service, Hospital / statistics & numerical data. Osteosarcoma / secondary. Osteosarcoma / surgery. Poland. Prognosis. Retrospective Studies. Sarcoma, Ewing / secondary. Sarcoma, Ewing / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317898.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Barton SJ, Ashdown DA, Ganta S, Wallace D: An unusual presentation of metastatic testicular tumour. J R Army Med Corps; 2005 Mar;151(1):30-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After chemotherapy, the undescended right testicle was resected along with a cord of non- obstructing inferior venal caval tumour which extended into the right atrium with tumour floating free within the atrium at the end of the cord of tumour.
  • The presentation, diagnosis and treatment of testicular tumours is described and the literature pertaining to testicular tumours in military personnel reviewed.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Pulmonary Embolism / diagnosis. Pulmonary Embolism / etiology. Teratoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Military Personnel. Neoplastic Cells, Circulating. Vascular Neoplasms / diagnosis. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery. Vena Cava, Inferior / pathology. Venous Thrombosis / diagnosis. Venous Thrombosis / surgery

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912681.001).
  • [ISSN] 0035-8665
  • [Journal-full-title] Journal of the Royal Army Medical Corps
  • [ISO-abbreviation] J R Army Med Corps
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • RESULTS: In all cases of hepatoblastoma and yolk sac tumor, both the total AFP and the L3 fraction were high, either before treatment or in the presence of malignant tumors.
  • Most of the cases of neonatal immature teratoma showed a high total AFP level during the neoinfantile period, however, the L3 fraction was around 10%, and decreased after surgical treatment.
  • As the total AFP and the AFP-L3 fraction were proportionally elevated, the patient was treated with additional surgical resection and chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


23. Sell S: Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol; 2008;29(3):161-80
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Identification of the cells in the liver that produce alpha-fetoprotein during development, in response to liver injury and during the early stages of chemical hepatocarcinogenesis led to the conclusion that maturation arrest of liver-determined tissue stem cells was the cellular process that gives rise to hepatocellular carcinomas.
  • When the cellular changes in these processes were compared to that of the formation of teratocarcinomas, the hypothesis arose that all cancers arise from maturation arrest of tissue-determined stem cells.
  • This was essentially a reinterpretation of the embryonal rest theory of cancer whereby tissue stem cells take the role of embryonal rests.
  • A corollary of the stem cell theory of the origin of cancer is that cancers contain the same functional cell populations as normal tissues: stem cells, transit-amplifying cells and mature cells.
  • However, the presence of cancer stem cells in tumors is believed to be responsible for the properties of immortalization, transplantability and resistance to therapy characteristic of cancers.
  • Current therapies for cancer (chemotherapy, radiotherapy, antiangiogenesis and differentiation therapy) are directed against the cancer transit-amplifying cells.
  • When these therapies are discontinued, the cancer reforms from the cancer stem cells.
  • Therapy directed toward interruption of the cell signaling pathways that maintain cancer stem cells could lead to new modalities to the prevention of regrowth of the cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplastic Stem Cells / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [Cites] Adv Cancer Res. 1963;7:383-474 [14153769.001]
  • [Cites] Exp Mol Pathol. 1964 Jun;86:242-61 [14194323.001]
  • [Cites] Exp Mol Pathol. 1964 Jun;86:279-86 [14194324.001]
  • [Cites] Vopr Med Khim. 1964 Jan-Feb;10:90-1 [14207501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1964 Sep;52:654-61 [14212538.001]
  • [Cites] Scand J Clin Lab Invest. 1956;8(2):174 [13351554.001]
  • [Cites] Helv Paediatr Acta. 1961 Dec;16:517-33 [14477298.001]
  • [Cites] J Clin Invest. 1960 Jul;39:1157-75 [13846364.001]
  • [Cites] Stem Cells. 2004;22(6):1049-61 [15536195.001]
  • [Cites] Curr Hematol Rep. 2005 May;4(3):186-90 [15865870.001]
  • [Cites] Haematologica. 2005 Jul;90(7):949-68 [15996933.001]
  • [Cites] Hepatology. 2000 Apr;31(4):948-55 [10733552.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1229-34 [11062533.001]
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Exp Biol Med (Maywood). 2001 May;226(5):377-408 [11393167.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):65-81 [11813887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2211-5 [11830647.001]
  • [Cites] Wound Repair Regen. 2001 Nov-Dec;9(6):467-82 [11896989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10567-70 [12149477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12865-70 [12297623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Haematologica. 2003 Apr;88(4):368-78 [12681963.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):901-4 [12665833.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):1996-2004 [2450643.001]
  • [Cites] Lab Invest. 1988 Nov;59(5):657-65 [2460696.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1347-63 [2474256.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1082-95 [2547506.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(2):87-115 [1346535.001]
  • [Cites] Int J Dev Biol. 1993 Mar;37(1):189-201 [8389577.001]
  • [Cites] Tumour Biol. 1993;14(2):116-30 [7687070.001]
  • [Cites] Genes Dev. 1993 Dec;7(12A):2298-307 [8253378.001]
  • [Cites] Lab Invest. 1994 Jan;70(1):6-22 [8302019.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Radiother Oncol. 1994 Jan;30(1):1-5 [8153374.001]
  • [Cites] Radiother Oncol. 1994 Jan;30(1):6-10 [8153382.001]
  • [Cites] Hepatology. 1995 Jun;21(6):1702-12 [7539398.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Rinsho Kyobu Geka. 1989 Feb;9(1):29-34 [9301895.001]
  • [Cites] Stem Cells. 1997;15(5):378-85 [9323801.001]
  • [Cites] Hepatology. 1998 Feb;27(2):317-31 [9462626.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1030-8 [9537443.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):497-507 [10488710.001]
  • [Cites] Cancer. 1952 Jan;5(1):24-44 [14886896.001]
  • [Cites] Biochem Biophys Res Commun. 1968 Mar 12;30(5):565-70 [4296319.001]
  • [Cites] Cancer Res. 1968 Jun;28(6):1210-1 [5658450.001]
  • [Cites] Proc Can Cancer Conf. 1969;8:9-30 [4389417.001]
  • [Cites] Cancer. 1970 Mar;25(3):551-63 [4313652.001]
  • [Cites] J Immunol. 1977 Jul;119(1):91-7 [68978.001]
  • [Cites] J Immunol. 1977 Jul;119(1):98-103 [68979.001]
  • [Cites] Radiat Res. 1977 Dec;72(3):455-68 [201960.001]
  • [Cites] Brain Res. 1978 Feb 17;142(1):182-6 [75046.001]
  • [Cites] J Natl Cancer Inst. 1978 Jan;60(1):19-26 [75267.001]
  • [Cites] Cancer Res. 1978 Apr;38(4):1092-8 [76508.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):3107-13 [79445.001]
  • [Cites] Br J Cancer. 1978 Jul;38(1):1-23 [356869.001]
  • [Cites] J Natl Cancer Inst. 1978 Sep;61(3):813-7 [278859.001]
  • [Cites] Cancer Res. 1979 May;39(5):1437-42 [85483.001]
  • [Cites] Biochemistry. 1979 May 29;18(11):2167-78 [87217.001]
  • [Cites] J Natl Cancer Inst. 1979 Sep;63(3):835-41 [89213.001]
  • [Cites] J Natl Cancer Inst. 1980 May;64(5):1147-52 [6154169.001]
  • [Cites] Cell Biol Int Rep. 1980 Mar;4(3):235-54 [6155219.001]
  • [Cites] C R Seances Acad Sci D. 1979 Dec 10;289(15):1157-60 [95002.001]
  • [Cites] Adv Cancer Res. 1980;31:125-226 [6250325.001]
  • [Cites] Prog Clin Biol Res. 1980;48:15-20 [7208516.001]
  • [Cites] Carcinogenesis. 1981;2(1):7-14 [7273292.001]
  • [Cites] Oncodev Biol Med. 1980;1(2):93-105 [6169057.001]
  • [Cites] Oncodev Biol Med. 1981;2(1-2):117-28 [6170952.001]
  • [Cites] Oncodev Biol Med. 1981;2(4):243-66 [6170955.001]
  • [Cites] Hepatology. 1982 Jan-Feb;2(1):77-86 [6172353.001]
  • [Cites] Cancer Res. 1971 Jun;31(6):821-5 [4326039.001]
  • [Cites] Int J Cancer. 1971 Nov 15;8(3):374-83 [5002872.001]
  • [Cites] Cancer Res. 1972 Jun;32(6):1184-9 [4624139.001]
  • [Cites] S Afr Med J. 1972 Sep 9;46(36):1290-7 [4118727.001]
  • [Cites] Cancer Res. 1972 Dec;32(12):2753-60 [4630092.001]
  • [Cites] Cancer Res. 1973 May;33(5):1010-5 [4122163.001]
  • [Cites] Cancer. 1973 May;31(5):1065-8 [4122298.001]
  • [Cites] Nature. 1952 Oct 11;170(4328):622-3 [13002388.001]
  • [Cites] J Infect Dis. 1958 Nov-Dec;103(3):239-62 [13611294.001]
  • [Cites] Rev Czech Med. 1962;8:214-25 [13933356.001]
  • [Cites] Transplantation. 1963 Apr;1:174-80 [14010646.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1723-30 [12970771.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8795-808 [14612419.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Jun;229(6):439-63 [15169963.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] J Exp Med. 1965 Sep 1;122(3):467-81 [4953873.001]
  • [Cites] Exp Mol Pathol. 1966 Apr;5(2):146-81 [5937381.001]
  • [Cites] J Natl Cancer Inst. 1967 Apr;38(4):549-52 [6025005.001]
  • [Cites] Eur J Cancer. 1966 Jun;2(2):131-4 [5965747.001]
  • [Cites] J Clin Invest. 1967 Jun;46(6):1010-6 [6067376.001]
  • [Cites] Immunochemistry. 1973 Jul;10(7):439-42 [4724800.001]
  • [Cites] J Natl Cancer Inst. 1974 Jan;52(1):133-7 [4359411.001]
  • [Cites] Cancer Res. 1974 Apr;34(4):865-71 [4814999.001]
  • [Cites] Cancer Res. 1974 Jun;34(6):1413-7 [4363658.001]
  • [Cites] J Natl Cancer Inst. 1974 May;52(5):1483-9 [4831436.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):289-91 [4835112.001]
  • [Cites] J Exp Med. 1974 Oct 1;140(4):1049-56 [4610074.001]
  • [Cites] J Exp Med. 1975 Feb 1;141(2):269-86 [46267.001]
  • [Cites] Nature. 1975 Nov 6;258(5530):70-73 [1186881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3585-9 [1059147.001]
  • [Cites] J Natl Cancer Inst. 1976 Mar;56(3):645-8 [56449.001]
  • [Cites] Nature. 1976 Sep 9;263(5573):146-8 [61561.001]
  • [Cites] Nature. 1976 Oct 21;263(5579):685-7 [62284.001]
  • [Cites] Radiat Res. 1977 Jan;69(1):54-64 [64991.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):526-30 [844919.001]
  • [Cites] Hum Pathol. 1981 Nov;12(11):959-63 [6172362.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1206-11 [6277460.001]
  • [Cites] Cancer Res. 1982 Nov;42(11):4855-61 [6181870.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1761-7 [6187438.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106(2):85-92 [6630286.001]
  • [Cites] Int Rev Cytol. 1983;85:63-107 [6363329.001]
  • [Cites] Am J Pathol. 1984 Feb;114(2):287-300 [6696045.001]
  • [Cites] Ann N Y Acad Sci. 1983;417:321-9 [6200040.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):11-22 [6746700.001]
  • [Cites] Adv Enzyme Regul. 1984;22:97-121 [6591771.001]
  • [Cites] Biochim Biophys Acta. 1984;738(4):219-36 [6394049.001]
  • [Cites] Brain Res. 1985 Sep;354(1):49-53 [2412659.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;407(4):387-405 [2413614.001]
  • [Cites] Lab Invest. 1987 Jan;56(1):4-22 [3025514.001]
  • [Cites] Differentiation. 1987;33(3):247-53 [3596087.001]
  • [Cites] Cancer Res. 1971 Jan;31(1):1-3 [5540951.001]
  • [Cites] Cancer Res. 1971 Feb;31(2):127-34 [5545265.001]
  • [Cites] Hepatology. 2006 Jan;43(1):2-8 [16374844.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):220-6 [16388309.001]
  • [Cites] Hepatology. 2006 Feb;43(2):316-24 [16440343.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):2012-8 [16479017.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Nat Med. 2006 Apr;12(4):410-6 [16532004.001]
  • [Cites] Liver Int. 2006 May;26(4):457-66 [16629650.001]
  • [Cites] Tumour Biol. 2006;27(2):59-70 [16557043.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [Cites] Curr Gene Ther. 2006 Oct;6(5):579-91 [17073603.001]
  • [Cites] Genetics. 2006 Nov;174(3):1069-72 [17121966.001]
  • [Cites] Stem Cell Rev. 2005;1(1):1-7 [17132868.001]
  • [Cites] Stem Cell Rev. 2005;1(3):197-205 [17142856.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1444-50 [17205516.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1077-87 [17383429.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1750-62 [17456779.001]
  • [Cites] Hepatology. 2007 May;45(5):1250-60 [17464997.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] Stem Cell Rev. 2007 Jan;3(1):1-6 [17873376.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2419-29 [17585168.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2476-87 [17641245.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1611-9 [17705295.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1451-61 [18316609.001]
  • [Cites] Hepatology. 2008 Mar;47(3):919-28 [18275073.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1749-58 [17891174.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1768-77 [18467658.001]
  • (PMID = 18612221.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112481-02; United States / NCI NIH HHS / CA / R01 CA071390; United States / NIEHS NIH HHS / ES / R01 ES009495-01A2; United States / NIDDK NIH HHS / DK / R01 DK057619-01A1; United States / NIDDK NIH HHS / DK / R01 DK057619; United States / NIDDK NIH HHS / DK / R01 DK057619-04; United States / NCI NIH HHS / CA / R01 CA074888-01A2; United States / NIEHS NIH HHS / ES / R01 ES009495-03; United States / NCI NIH HHS / CA / R01 CA074888-02; United States / NCI NIH HHS / CA / R01 CA112481-03; United States / NCI NIH HHS / CA / R01 CA071390-04; United States / NIEHS NIH HHS / ES / R01 ES009495-02; United States / NCI NIH HHS / CA / R01 CA112481; United States / NIDDK NIH HHS / DK / R01 DK057619-05; United States / NIDDK NIH HHS / DK / R01 DK057619-02; United States / NCI NIH HHS / CA / R01 CA112481-04; United States / NIEHS NIH HHS / ES / R01 ES009495; United States / NIEHS NIH HHS / ES / R01 ES009495-04; United States / NCI NIH HHS / CA / R01 CA112481-01A1; United States / NCI NIH HHS / CA / R01 CA074888-04; United States / NIEHS NIH HHS / ES / R01 ES009495-05; United States / NCI NIH HHS / CA / R01 CA074888; United States / NCI NIH HHS / CA / R01 CA074888-03; United States / NIDDK NIH HHS / DK / R01 DK057619-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 188
  • [Other-IDs] NLM/ NIHMS68144; NLM/ PMC2679671
  •  go-up   go-down


24. Sassa N, Yoshino Y, Matsukawa Y, Komatsu T, Yoshikawa Y, Yamamoto T, Hattori R, Gotoh M: [Case report of malignant sertoli cell tumor]. Nihon Hinyokika Gakkai Zasshi; 2008 Jul;99(5):656-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He received 3 courses of chemotherapy with BEP (bleomycine, etoposide, cisplatin), but, lymph node size did not change.
  • After he underwent a CT guided lymph node biopsy, his pathologic diagnosis was viable embryonal carcinoma.
  • We selected CPT-11 and nedaplatin for his salvage chemotherapy, but lymph node lesions did not change.
  • After he received 3 courses of chemotherapy, we performed retroperitoneal lymphadenectomy.
  • His pathologic diagnosis was viable sertoli cell tumor, malignant type.
  • After 30 days, he had multiple liver metastases ane died 27 months after orchiectomy.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Organoplatinum Compounds / administration & dosage. Salvage Therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697473.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 7673326042 / irinotecan; 8UQ3W6JXAN / nedaplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Jiang XL, Du LL, Yang S, Chen LS, Lu GX: Suppression of teratocarcinoma growth by soluble TRAIL gene expression driven by the progression-elevated gene-3 promoter. Cancer Biol Ther; 2009 Aug;8(15):1517-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transfection of embryonal carcinoma (EC) cells with the plasmid resulted in significant cellular apoptosis and elevated expression of death receptor 4 (DR4) and death receptor 5 (DR5).
  • Histological examination and serum analyses showed the absence of detectable toxicity in all examined tissues, including liver.
  • Our results demonstrate that sTRAIL gene expression driven by the rPEG promoter may enable effective gene therapy against teratocarcinoma.
  • [MeSH-major] Antigens, Differentiation / genetics. Cell Cycle Proteins / genetics. Genetic Therapy. Peptide Fragments / genetics. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Teratocarcinoma / therapy
  • [MeSH-minor] Animals. Apoptosis. Cholesterol / administration & dosage. DNA, Recombinant / administration & dosage. DNA, Recombinant / genetics. Drug Carriers. Fatty Acids, Monounsaturated / administration & dosage. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Protein Phosphatase 1. Quaternary Ammonium Compounds / administration & dosage. Rats. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / therapeutic use. Simian virus 40 / genetics. Telomerase / genetics. Transfection. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823015.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Cell Cycle Proteins; 0 / DNA, Recombinant; 0 / Drug Carriers; 0 / Fatty Acids, Monounsaturated; 0 / Myd116 protein, rat; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Quaternary Ammonium Compounds; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Recombinant Fusion Proteins; 0 / soluble tumor necrosis factor-related apoptosis-inducing ligand (114-281), rat; 113669-21-9 / 1,2-dioleoyloxy-3-(trimethylammonium)propane; 97C5T2UQ7J / Cholesterol; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; EC 3.1.3.16 / PPP1R15A protein, human; EC 3.1.3.16 / Protein Phosphatase 1
  •  go-up   go-down






Advertisement